Share on StockTwits

Shares of Medivation (NASDAQ:MDVN) were the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 5,107,671 shares, a growth of 36.3% from the April 30th total of 3,746,145 shares, reports. Approximately 6.9% of the company’s stock are short sold. Based on an average trading volume of 1,325,146 shares, the short-interest ratio is currently 3.9 days.

A number of analysts have recently weighed in on MDVN shares. Analysts at Zacks reiterated a “neutral” rating on shares of Medivation in a research note on Monday, May 26th. They now have a $72.00 price target on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Medivation in a research note on Thursday, May 22nd. They set a “buy” rating and a $81.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of Medivation from a “sell” rating to a “hold” rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $90.69.

Medivation (NASDAQ:MDVN) opened at 76.25 on Thursday. Medivation has a 52-week low of $44.51 and a 52-week high of $88.20. The stock has a 50-day moving average of $65.06 and a 200-day moving average of $68.09. The company’s market cap is $5.835 billion.

Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.18) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.09) by $0.09. The company had revenue of $87.19 million for the quarter, compared to the consensus estimate of $94.64 million. During the same quarter last year, the company posted ($0.36) earnings per share. Medivation’s revenue was up 88.9% compared to the same quarter last year. Analysts expect that Medivation will post $1.35 EPS for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.